Next Article in Journal
Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
Next Article in Special Issue
Preimplantation Genetic Testing for Polygenic Disease Relative Risk Reduction: Evaluation of Genomic Index Performance in 11,883 Adult Sibling Pairs
Previous Article in Journal
A Novel Mechanism of bta-miR-210 in Bovine Early Intramuscular Adipogenesis
Previous Article in Special Issue
Mother and Embryo Cross-Communication
Review

Preimplantation Genetic Testing for Chromosomal Abnormalities: Aneuploidy, Mosaicism, and Structural Rearrangements

Zouves Foundation for Reproductive Medicine and Zouves Fertility Center, 1241 East Hillsdale Blvd, Suite 100, Foster City, CA 94404, USA
Genes 2020, 11(6), 602; https://doi.org/10.3390/genes11060602
Received: 12 May 2020 / Revised: 25 May 2020 / Accepted: 27 May 2020 / Published: 29 May 2020
(This article belongs to the Special Issue EmbryoGenetics)
There is a high incidence of chromosomal abnormalities in early human embryos, whether they are generated by natural conception or by assisted reproductive technologies (ART). Cells with chromosomal copy number deviations or chromosome structural rearrangements can compromise the viability of embryos; much of the naturally low human fecundity as well as low success rates of ART can be ascribed to these cytogenetic defects. Chromosomal anomalies are also responsible for a large proportion of miscarriages and congenital disorders. There is therefore tremendous value in methods that identify embryos containing chromosomal abnormalities before intrauterine transfer to a patient being treated for infertility—the goal being the exclusion of affected embryos in order to improve clinical outcomes. This is the rationale behind preimplantation genetic testing for aneuploidy (PGT-A) and structural rearrangements (-SR). Contemporary methods are capable of much more than detecting whole chromosome abnormalities (e.g., monosomy/trisomy). Technical enhancements and increased resolution and sensitivity permit the identification of chromosomal mosaicism (embryos containing a mix of normal and abnormal cells), as well as the detection of sub-chromosomal abnormalities such as segmental deletions and duplications. Earlier approaches to screening for chromosomal abnormalities yielded a binary result of normal versus abnormal, but the new refinements in the system call for new categories, each with specific clinical outcomes and nuances for clinical management. This review intends to give an overview of PGT-A and -SR, emphasizing recent advances and areas of active development. View Full-Text
Keywords: PGT-A; PGT-SR; mosaicism; embryo genetics; chromosomal abnormality PGT-A; PGT-SR; mosaicism; embryo genetics; chromosomal abnormality
Show Figures

Figure 1

MDPI and ACS Style

Viotti, M. Preimplantation Genetic Testing for Chromosomal Abnormalities: Aneuploidy, Mosaicism, and Structural Rearrangements. Genes 2020, 11, 602. https://doi.org/10.3390/genes11060602

AMA Style

Viotti M. Preimplantation Genetic Testing for Chromosomal Abnormalities: Aneuploidy, Mosaicism, and Structural Rearrangements. Genes. 2020; 11(6):602. https://doi.org/10.3390/genes11060602

Chicago/Turabian Style

Viotti, Manuel. 2020. "Preimplantation Genetic Testing for Chromosomal Abnormalities: Aneuploidy, Mosaicism, and Structural Rearrangements" Genes 11, no. 6: 602. https://doi.org/10.3390/genes11060602

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop